To evaluate the effectiveness of an early, moderate BP reduction in patients with acute cerebral ischemia in comparison to restrictive antihypertensive therapy.
- Candesartan cilexetil (Atacand®)Drug
Intervention Desc: AT1 receptor antagonist (antihypertensive)
- Antihypertensives Drug
Intervention Desc: This category includes all BP lowering drugs in stroke prevention trials
Double-blind, randomized, multicenter trial with a planned enrollment of 500 patients. 342 patients randomized from 53 centers.
Patients randomized to receive AT1 receptor antagonist candesartan cilexitil or placebo for 7 days. The placebo group is treated with candesartan if they are hypertensive after 7 days. Normotensive patients are followed up but not treated. The treatment group is also continued on candesartan. If hypertension remains, a combination therapy with other substance classes is possible. Follow-up period of 12 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Patient morbidity (functional status as measured with Rankin Scale and Barthel Index, degree of motor deficit by NIH scale) and mortaility rates after 3 months.|